BibbInstruments

BibbInstruments Intangible Assets

The Intangible Assets of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is 30.77 M SEK. In the previous year, Intangible Assets was 27.63 M SEK — a change of 11.37% (higher).

Intangible Assets

30.77 MSEK

YoY

11.37%

Last updated:

Intangible Assets of BibbInstruments is 2025 30.77 M SEK. Intangible Assets of BibbInstruments was 2024 27.63 M SEK. It decreases by 11.37% higher compared to the previous year.

The BibbInstruments Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
3.74 M SEK
Jan 1, 2019
9.13 M SEK
Jan 1, 2020
10.47 M SEK
Jan 1, 2021
15.01 M SEK
Jan 1, 2022
19.65 M SEK
Jan 1, 2023
22.71 M SEK
Jan 1, 2024
27.63 M SEK
Jan 1, 2025
30.77 M SEK
The BibbInstruments Intangible Assets history
YEARIntangible AssetsYoY
30.77 MSEK+11.37%
27.63 MSEK+21.67%
22.71 MSEK+15.55%
19.65 MSEK+30.90%
15.01 MSEK+43.41%
10.47 MSEK+14.70%
9.13 MSEK+143.97%
3.74 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Intangible Assets of BibbInstruments is 30.77 M SEK in 2025.

Intangible Assets of BibbInstruments changed from 27.63 M SEK to 30.77 M SEK, representing a 11.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's BibbInstruments historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BibbInstruments

All Key Metrics — BibbInstruments